Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01586403 · ClinicalTrials.gov registry record · Phase 1
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
A Phase 1 study of Melanoma, sponsored by Loyola University.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01586403: Active Phase 1 study of Melanoma, sponsored by Loyola University.
NCT01586403 is a Phase 1 study of Melanoma that is active but no longer recruiting, run by Loyola University. The registered enrollment target is 14 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01586403, a Phase 1 study of Melanoma, is active but no longer recruiting, sponsored by Loyola University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
Primary Outcome
Establish the recommended phase two dose of autologous T cell receptor transduced T cells when administered with low dose IL-2 to stage IV melanoma patients
Conditions Studied
Interventions
- BIOLOGICAL Dose 1
- BIOLOGICAL Dose 2
- BIOLOGICAL Dose 3
- BIOLOGICAL Dose 4
Study Locations (1)
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-07 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
What the registry record for NCT01586403 still lists
NCT01586403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Dose 1 is the first listed.
NCT01586403 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01586403 about?
NCT01586403 is a clinical study titled "Transfer of Genetically Engineered Lymphocytes in Melanoma Patients". This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
What is the current status of trial NCT01586403?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-07. Estimated completion is 2028-09.
What conditions does trial NCT01586403 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT01586403?
The interventions under investigation include: Dose 1 (BIOLOGICAL), Dose 2 (BIOLOGICAL), Dose 3 (BIOLOGICAL), Dose 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01586403?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01586403 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01586403's enrollment target sits among peer trials
14 244th of 266 higher than 20 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia